Quinolone arthropathy in animals versus children

Clinical Infectious Diseases

Volumn 25, Issue 5, 1997, Pages 1196-1204

  Burkhardt, John E ^a   Walterspiel, Juan N ^b   Schaad, Urs B ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN;

AGE; ARTHROPATHY; ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0030827533     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516119     Document Type: Article

References (16)

1. Machida M, Kusajima H, Aijima H, Maeda A, Ishida R, Uchida H. Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. Toxicol Appl Pharmacol 1990;105(suppl. 3):403-12.
2. Schaad UB, Salam MA, Aujard Y, Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14(suppl 1):1-9.
3. Richard DA, Nousia-Arvanitakis S, Sollich V, et al. Oral ciprofloxacin versus intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatr Infect Dis J 1997;16:572-8.
4. Van Wijk JAE, de Jong TPVM, Van Cool JD, Boemers TM, Voorman M. Using quinolones in urinary tract infections in children. Advances in Antimicrobial and Antineoplastic Chemotherapy 1992;11(suppl 2): 157-61.
5. Gendrel D, Moreno JL, Nduwimana M, Baribwira C, Raymond J. One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin Infect Dis 1997;24:83.
6. Bethell DB, Day NPJ, Dung NM, et al. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob Agents Chemother 1996;40:2167-72.
7. Vinh H, Wain J, Hahn VTN, et al. Two or three days of ofloxacin for uncomplicated multi-drug resistant typhoid fever in children. Antimicrob Agents Chemother 1996;40:958-61.
8. Hien TT, Bethell DB, Hoa NTT, et al. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995;20: 917-23.
9. Rathore MH, Bux D, Hasan M. Multidrug-resistant Salmonella typhi in Pakistani children: clinical features and treatment. South Med J 1996; 89:2:235-7.
10. Cuevas LE, Kazembe P, Mughogho GK, Tilloston GS, Hart CA. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J Infect Dis 1995;171(suppl 3):728-31.
11. Arguedas-Mohs A, Loaiza C, Riviera R, et al. CSF penetration of iv trovafloxacin in children [abstract 4]. In: Program and abstracts of the First International Pediatric Infectious Disease Conference (Monterey, CA). Pediatric Infectious Diseases Society of America and European Society for Paediatric Infectious Diseases, 1995.
12. Barry AL, Fuchs PC, Brown SD. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Antimicrob Agents Chemother 1996;40:2431-3.
13. Hopkins S, Williams D, Dunne M, Marinovich L, Edeline M, Utt E, Dutse AI. A randomized, controlled trial of oral or iv trovafloxacin vs. ceftriaxone in the treatment of epidemic meningococcal meningitis [LB 21 (late breaker)]. In: program addendum to Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). American Society for Microbiology, Washington, D.C., 1996:11.
14. Linseman DA, Hamptom LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse: morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol 1995;28:59-64.
15. Kato M, Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundam Appl Toxicol 1988;11:110-9.
16. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5.